Type 2 diabetes mellitus as a possible risk factor for myasthenia gravis: a case–control study

Background A certain number of myasthenia gravis (MG) patients clinically had type 2 diabetes mellitus (T2DM) prior to MG onset, which suggests that the onset of MG may correlate with the history of T2DM. This study aimed to examine the correlation between MG and T2DM. Methods In a single-center, retrospective, 1:5 matched case–control study, all 118 hospitalized patients with a diagnosis of MG from 8 August 2014 to 22 January 2019 were enrolled. In total, four datasets with different sources of the control group were retrieved from the electronic medical records (EMRs). Data were collected at the individual level. A conditional logistic regression analysis was used to test the risk of MG associated with T2DM. Findings The risk of MG was significantly associated with T2DM, and there were notable differences by sex and age. Whether compared to the general population, general hospitalized patients without autoimmune diseases (AIDs), or patients with other AIDs except MG, women aged over 50 years with T2DM had an increased risk of MG. The mean onset age of diabetic MG patients was more than that of the non-diabetic MG patients. Interpretation This study demonstrates that T2DM is strongly associated with the subsequent risk of MG and varies significantly by sex and age. It reveals that diabetic MG may be a unique subtype that is different from the conventional MG subgroup classification. More clinical and immunological features of diabetic MG patients need to be explored in further studies.

[1]  Y. Liu,et al.  Diabetes mellitus aggravates humoral immune response in myasthenia gravis by promoting differentiation and activation of circulating Tfh cells. , 2022, Clinical immunology.

[2]  C. Piperi,et al.  Unravelling the role of Receptor for advanced glycation end products (RAGE) and its ligands in Myasthenia Gravis. , 2020, ACS chemical neuroscience.

[3]  S. Luo,et al.  HLA in myasthenia gravis: From superficial correlation to underlying mechanism. , 2019, Autoimmunity reviews.

[4]  Antonios G. Mikos,et al.  Microfluidic devices for disease modeling in muscle tissue. , 2019, Biomaterials.

[5]  Zhongjun Yan,et al.  Clinical differences of early and late-onset myasthenia gravis in 985 patients , 2018, Neurological research.

[6]  Jong Seong Roh,et al.  Damage-Associated Molecular Patterns in Inflammatory Diseases , 2018, Immune network.

[7]  R. Ruff,et al.  Nature and Action of Antibodies in Myasthenia Gravis. , 2018, Neurologic clinics.

[8]  M. Pasnoor,et al.  Diagnosis of Myasthenia Gravis. , 2018, Neurologic clinics.

[9]  Yichong Li,et al.  Prevalence and Ethnic Pattern of Diabetes and Prediabetes in China in 2013 , 2017, JAMA.

[10]  F. Zouaidia,et al.  Expression of receptor for advanced glycation end-products (RAGE) in thymus from myasthenia patients. , 2017, Revue neurologique.

[11]  N. Gilhus,et al.  Autoantibody profile and clinical characteristics in a cohort of Chinese adult myasthenia gravis patients , 2016, Journal of Neuroimmunology.

[12]  Francesca Aloisi,et al.  Sex-based differences in autoimmune diseases. , 2016, Annali dell'Istituto superiore di sanita.

[13]  K. Kondo,et al.  Late-onset myasthenia gravis is predisposed to become generalized in the elderly , 2016, eNeurologicalSci.

[14]  H. Chiu,et al.  Risk of diabetes mellitus among patients with myasthenia gravis , 2015, Acta neurologica Scandinavica.

[15]  Jacqueline A Palace,et al.  Clinical Features and Diagnostic Usefulness of Antibodies to Clustered Acetylcholine Receptors in the Diagnosis of Seronegative Myasthenia Gravis. , 2015, JAMA neurology.

[16]  R. Lewis Myasthenia gravis: New therapeutic approaches based on pathophysiology , 2013, Journal of the Neurological Sciences.

[17]  Jiang He,et al.  Prevalence and control of diabetes in Chinese adults. , 2013, JAMA.

[18]  B. Shi,et al.  Increased PD-1 on CD4(+)CD28(-) T cell and soluble PD-1 ligand-1 in patients with T2DM: association with atherosclerotic macrovascular diseases. , 2013, Metabolism: clinical and experimental.

[19]  D. Lacomis,et al.  Characteristics of late-onset myasthenia gravis , 2012, Journal of Neurology.

[20]  V. Urbonaviciute,et al.  High‐mobility group box 1 represents a potential marker of disease activity and novel therapeutic target in systemic lupus erythematosus , 2011, Journal of internal medicine.

[21]  Hulun Li,et al.  Activation of the receptor for advanced glycation end products (RAGE) exacerbates experimental autoimmune myasthenia gravis symptoms. , 2011, Clinical immunology.

[22]  D. DeMets,et al.  Statistical association and causation: contributions of different types of evidence. , 2011, JAMA.

[23]  D. Sanders,et al.  Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity , 2009, The Lancet Neurology.

[24]  J. Aarli Myasthenia Gravis in the Elderly , 2008, Annals of the New York Academy of Sciences.

[25]  M. Zorzetto,et al.  The receptor for advanced glycation end products and its ligands: a new inflammatory pathway in lung disease? , 2006, Modern Pathology.

[26]  T. Imaizumi,et al.  Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. , 2005, Current pharmaceutical design.

[27]  P. Tonali,et al.  Thymoma in patients with MG , 2002, Neurology.

[28]  D. Lawlor,et al.  The association between components of adult height and Type II diabetes and insulin resistance: British Women's Heart and Health Study , 2002, Diabetologia.

[29]  P. Petrow,et al.  Identification of the advanced glycation end products Nε-carboxymethyllysine in the synovial tissue of patients with rheumatoid arthritis , 2002, Annals of the rheumatic diseases.

[30]  C. Hennekens,et al.  Contributions of different types of evidence. , 2001 .

[31]  A. B. Hill,et al.  "The Environment and Disease: Association or Causation?" (1965), by Austin Bradford Hill , 2017 .

[32]  B. Team British Women's Heart and Health Study: Data and study instruments , 2008 .

[33]  H. Nakazora,et al.  Myasthenia gravis and diabetes mellitus: a 35-year retrospective study. , 2007, Internal medicine.